AIM ImmunoTech (AIM)
(Delayed Data from AMEX)
$0.40 USD
-0.04 (-8.38%)
Updated May 10, 2024 03:59 PM ET
After-Market: $0.41 +0.01 (2.50%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
AIM 0.40 -0.04(-8.38%)
Will AIM be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for AIM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for AIM
Biotech Alert: Searches spiking for these stocks today
Biotech Alert: Searches spiking for these stocks today
AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast
AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®
Aimia Inc. Announces Upcoming Q1 2024 Results